PORTFOLIO
ENGINE BIOSCIENCES Technology + Biology Technology company pioneering unique data-driven approaches for curing complex diseases. Applying comprehensive computational/AI and experimental biology platforms for more efficient and effective discovery of new therapies or improvements to existing products. |
SYNLOGIC (NASDAQ: SYBX)
Biotech Pioneering the development of a novel class of living medicines, Synthetic Biotics™, based on its proprietary drug discovery and development platform. Synlogic’s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Now listed on NASDAQ. |
SENTI BIOSCIENCES Biotech Senti Biosciences is developing novel therapeutics to solve challenging and complex diseases. Founded in 2016 and headquartered in the San Francisco Bay Area, Senti leverages expertise in cell engineering and biological programming to build the future of gene and cell based therapies. |
ENLEOFEN BIO
Biotech Transforming the treatment of fibrosis through first-in-class antibody therapeutics. Currently in preclinical stage. Based on breakthrough discoveries made at Duke-NUS Medical School and National Heart Centre Singapore. |
LEXENT BIO Biotech Based in the USA, Lexent Bio is building novel technology to change the way we diagnose and treat cancer. Lexent leverages expertise in bioinformatics and genomic science to build the future of oncology diagnostics. |
ASLAN PHARMACEUTICALS (TWSE: 6497) Biopharmaceutical ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies. Since its founding, ASLAN has raised over $100 million in financing, formed innovative partnerships with pharmaceutical industry leaders and developed four therapeutic medicines that target cancers for which there are few effective treatments. Now listed on the Taiwan Stock Exchange. |
ZUZU HOSPITALITY SOLUTIONS
Tech (Travel) ZUZU Hospitality Solutions delivers a simple, software and service, sales and marketing solution, for independent economy hotels. ZUZU disaggregates the chain economy hotel experience, working with independent hotels to offer services such as online distribution; revenue management; bookkeeping and procurement normally only available to major chains. |
ETRON TECHNOLOGY AND eYs3D MICROELECTRONICS
Tech (VR / IoT) Etron is a world-leading fabless IC design and product company, based and publicly listed in Taiwan. Etron and its subsidiaries eYs3D and eCapture have developed cutting-edge hardware and software solutions feeding into the virtual reality (VR), IoT, computer vision, AI and robotics spaces, supplying to world-leading companies in USA and Asia, as well as directly to the consumer. These include 3D and spherical image and video cameras, 3D depth-sensing, and "robot eye" solutions. Goodman Capital is working with the companies on corporate development, product strategies, marketing, and roll-out. |
VIGILYTICA Biotech + Software Technology commerciali-zation platform focused on bringing innovative hardware, software and analytics to market for agrifood applications in Asia. |
REEBONZ - EXITED
Tech (E-commerce) Asia's leading platform for buying and selling luxury products. Goodman Capital partnered and co-invested with Reebonz to enter the Myanmar market, launching the online presence as well as an offline showroom, marking the first major international luxury retail option in the country. |